NB3.F Neurocrine Biosciences Inc

Healthcare Pharmaceuticals Frankfurt Exchange
155.45 EUR
Close of Nov 12, 2026
102.55 160.50
Market cap
EUR 15.7B
P/E
26.8x
P/B
4.41x
ROE
18.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NB3.F undervalued?

Graham number
Price155.45
Graham value67.79
Premium129.3%

NB3.F trades 129.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Neurocrine Biosciences Inc fundamental analysis

No fundamental analysis for Neurocrine Biosciences Inc yet.

Neurocrine Biosciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under th…

Full company profile